Presentation is loading. Please wait.

Presentation is loading. Please wait.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Published byThiago Fidalgo Sabrosa Modified over 6 years ago

Similar presentations

Presentation on theme: "Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation."— Presentation transcript:

1 Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study  Gabriela Senti, MD, Seraina von Moos, MD, Fabian Tay, MD, Nicole Graf, PhD, Theodor Sonderegger, MSc, Pål Johansen, PhD, Thomas M. Kündig, MD  Journal of Allergy and Clinical Immunology  Volume 129, Issue 1, Pages (January 2012) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Participant flow. Flow diagram characterizing the study progress and participant flow through the different trial phases. Syst, Systemic. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Patient-reported treatment outcome. Patients rated the general improvement/deterioration of hay fever symptoms on a scale from −100 (worst possible deterioration) to +100 (best possible improvement) during the seasons 2008 (treatment) and 2009 (follow-up). Box plots show the median, the 10th, 25th, 75th, and 90th percentiles, and outliers. Intergroup comparison by Mann-Whitney multiple testing with Hochberg procedure adjustment. ∗P < .05. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Mean VAS symptom score for pollen season 2008 (upper panel) and 2009 (lower panel). Mean weekly VAS symptom scores (except lung symptoms) of the 100HEP group compared with those of the placebo group (left axis). For each patient, the sum of all symptom scores was calculated and divided by the number of symptoms. The continuous line shows the weekly pollen counts in Zurich (right axis). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Local drug-related AEs. A, Numbers of the most frequent local drug-related AEs as reported in the different treatment groups. B, Frequency of local side effects per patch sequence. Distribution of the frequency of local AEs was tested by using the χ2 test. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation."

Similar presentations

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial  Kaarina.

Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial  Kaarina.
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.
Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy  Harold Nelson, MD, Shannon Cartier, MSc,

Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy  Harold Nelson, MD, Shannon Cartier, MSc,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy  Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy  Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.
Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber  Friedrich Horak, MD, Petra.

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber  Friedrich Horak, MD, Petra.
Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis  Anne K. Ellis, MD, MSc, FRCPC, Charles.

Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis  Anne K. Ellis, MD, MSc, FRCPC, Charles.
Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract  Sheila M. Amar, MD, Ronald.

Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract  Sheila M. Amar, MD, Ronald.

Similar presentations

Ads by Google